

A new approach to treat Alzheimer's disease, potentially targeting the root cause of memory decline

- The ACT-AD and LIFT-AD trials are evaluating if a new investigational drug is safe and effective in improving symptoms of mild to moderate Alzheimer's disease.
- The investigational drug of the ACT-AD and LIFT-AD trials is designed to:
  - boost a repair and regenerative pathway for brain cells
  - promote brain health and function

## Alzheimer's Disease Clinical Trials

You or someone you know may be eligible if you:

- Are between 55 and 85 years of age
- Have been diagnosed with Alzheimer's disease
- Have a reliable and capable support person/caregiver



Go to [athiraclinicaltrials.com](https://athiraclinicaltrials.com) to find more information about the trial taking place near you

*\* The safety and efficacy of this investigational drug for the treatment of mild to moderate Alzheimer's has not been previously established.  
Talk to your doctor about participating in the ACT-AD or LIFT-AD trial.*

Trial sponsored by  
  
Athira  
PHARMA

Version 1 | 4 Mar 2021